BCI

BoardWare Announces 2023 Annual Results

Retrieved on: 
Tuesday, March 26, 2024
GBA, Government, Culture, BCI, Construction, Growth, Sport, Policy, Wheelchair, Artificial intelligence of things, Beihang University, Greater, COVID-19, Research, Accreditation, Software, Sale, App Store (iOS/iPadOS), AI, Web 3.0, Investment, Tourism, SME, Commerce, Zone, Artificial intelligence, Vendor

HONG KONG, Mar 26, 2024 - (ACN Newswire) - BoardWare Intelligence Technology Limited ("BoardWare" or together with its subsidiaries, the "Group"; stock code: 1204.HK), a leading company in the Greater Bay Area ("GBA") that offers comprehensive, high-quality and end-to-end enterprise IT solutions, today announced its annual results for the year ended 31 December 2023 ("2023" or the "Year").

Key Points: 
  • HONG KONG, Mar 26, 2024 - (ACN Newswire) - BoardWare Intelligence Technology Limited ("BoardWare" or together with its subsidiaries, the "Group"; stock code: 1204.HK), a leading company in the Greater Bay Area ("GBA") that offers comprehensive, high-quality and end-to-end enterprise IT solutions, today announced its annual results for the year ended 31 December 2023 ("2023" or the "Year").
  • The potential demands of various IT solutions resumed along with the end of the influence from COVID-19 pandemic.
  • With regard to business segments, the revenue from enterprise IT solutions increased 27.9% to HK$456.2 million.
  • Headquartered in Macao, BoardWare Intelligence Technology Limited is the leading company in the Macao IT solutions market.

Stifel Initiates Research Coverage of ONWARD® Medical with a Buy Rating and Target Price of EUR 12.00

Retrieved on: 
Tuesday, April 9, 2024
Buy, EUR, Target price, BCI, Target, Research, Euronext, ARC, Movement, SCI

EINDHOVEN, the Netherlands, April 09, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announced that Stifel, a US-based full-service investment bank, has initiated coverage of ONWARD Medical with a Buy rating and Target Price of EUR 12.00 per share.

Key Points: 
  • EINDHOVEN, the Netherlands, April 09, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announced that Stifel, a US-based full-service investment bank, has initiated coverage of ONWARD Medical with a Buy rating and Target Price of EUR 12.00 per share.
  • This is a premium of 140% to the closing price of EUR 5.00 on April 8, 2024.
  • The initiation report was published April 8, 2024.
  • Stifel joins four other banks whose analysts cover ONWARD Medical, all of which maintain Buy ratings and Target Prices at substantial premiums to the current share price.

ONWARD® Medical Submits De Novo Application to FDA for its ARC-EX® System

Retrieved on: 
Tuesday, April 2, 2024
De novo, DPT, BCI, Arm, Paralysis, Evaluation, Doctor of Philosophy, Quality of life, Euronext, BDD, Annual report, Craig Hospital, Spinal cord, Safety, ARC, Food, Marketing, FDA, SCI, NCS, Movement, Hand, Medical device

EINDHOVEN, the Netherlands, April 02, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to improve or restore movement, function, and independence in people with spinal cord injury (SCI), today announces it has submitted its De Novo application to the US Food and Drug Administration (FDA) to allow marketing of its breakthrough ARC-EX System to restore function of the upper extremities after SCI.

Key Points: 
  • The submission marks an historic milestone for the Company in its mission to restore mobility and function for people with SCI.
  • Once cleared by the FDA, ARC-EX will be the first-ever spinal cord stimulation therapy to restore hand and arm function after SCI and the first commercial product for ONWARD Medical.
  • “We are delighted to be one step closer to bringing our breakthrough ARC-EX System to people living with SCI after submitting this De Novo application for regulatory clearance in the United States,” said ONWARD Medical CEO Dave Marver.
  • The ARC-EX System was previously awarded FDA Breakthrough Device Designation (BDD) for upper limb function, which provided prioritized FDA review, the opportunity to interact with FDA experts, and the potential for additional reimbursement.

Synchron Launches Patient Registry for Stentrode Brain Computer Interface

Retrieved on: 
Monday, April 8, 2024
Medical Devices, Health, Neurology, Health Technology, Other Health, Biotechnology, Brain, BCI, Motor cortex, Communication, Patient, UPMC, University, Disability studies, Movement, Physician, Pathology, Medical device

The Synchron BCI represents a novel approach to restoring functionality in patients with limited mobility.

Key Points: 
  • The Synchron BCI represents a novel approach to restoring functionality in patients with limited mobility.
  • By leveraging the natural highways of the brain, an individual’s blood vessels, the device is implanted in the brain without the need for invasive brain surgery.
  • “We are thrilled to launch our community-centered BCI registry,” said Tom Oxley, CEO & Founder, Synchron.
  • For more information about the Synchron BCI and our registry, visit https://synchronbci.com .

Corix Laser-Focused on Championing the Transition to Cleaner Energy

Retrieved on: 
Monday, April 8, 2024
Nexus, BCI, University, Heat, Hospital, History, Carbon, City, Crown corporations of Canada, Water

VANCOUVER, BC, April 8, 2024 /PRNewswire/ - Corix District Energy Holdings LP (Corix) announced last week a new chapter in its North American thermal energy journey.

Key Points: 
  • VANCOUVER, BC, April 8, 2024 /PRNewswire/ - Corix District Energy Holdings LP (Corix) announced last week a new chapter in its North American thermal energy journey.
  • Building on a deeply rooted history in the US and Canadian utility spaces and with its water and wastewater business merged into Nexus Water Group, Corix is now laser-focused on continuing to champion the transition to cleaner energy by providing heating and cooling to cities, communities and campuses across North America.
  • "Corix is a thermal energy leader with a history extending more than 100 years in the US and 20-plus years in Canada," said Corix President & CEO, Lisa Sparrow.
  • "We're now directing our focus towards the transition to cleaner energy.

Mount Sinai Is First in New York to Test Revolutionary Brain-Computer Implant Designed to Map Brain Activity in Unprecedented Detail

Retrieved on: 
Friday, March 22, 2024
Principal, Electric potential, Speech, Culture, Brain, BCI, Health, Assistant, Associate, Patient, DSM-IV codes, Research, Electrophysiology, Doctor of Philosophy, Translation, MD, Quality of life, Science, Behavior, Mount Sinai Health System, Medical imaging

A brain-computer interface (BCI) is a system that deciphers brain signals and translates them into commands for external technologies.

Key Points: 
  • A brain-computer interface (BCI) is a system that deciphers brain signals and translates them into commands for external technologies.
  • The film is one-fifth the thickness of a human hair and was designed to be implanted and removed by neurosurgeons without damaging brain tissue.
  • Dr. Rapoport also serves as the Scientific Director of Mount Sinai BioDesign, a medical technology prototyping center and incubator housed within the Mount Sinai Health System.
  • All Precision Neuroscience research at Mount Sinai is conducted by independent investigators without financial ties to the company.

Precision Neuroscience Expands Clinical Research In Brain–Computer Interface

Retrieved on: 
Friday, March 22, 2024
Brain, BCI, Motor cortex, Assistant, Associate, Partnership, University, Patient, Deep brain stimulation, DSM-IV codes, Research, Sale, Electrode, Parkinson's disease, Trial of the century, Behavior, Hospital, Optimism, Precision, DBS, Mount Sinai Health System, Movement, Hand, Health, Medical device

NEW YORK, March 22, 2024 (GLOBE NEWSWIRE) -- Brain–computer interface (BCI) company Precision Neuroscience Corporation (Precision) today announced the launch of two new clinical study sites, at Mount Sinai Health System and Perelman School of Medicine at the University of Pennsylvania (Penn Medicine).

Key Points: 
  • NEW YORK, March 22, 2024 (GLOBE NEWSWIRE) -- Brain–computer interface (BCI) company Precision Neuroscience Corporation (Precision) today announced the launch of two new clinical study sites, at Mount Sinai Health System and Perelman School of Medicine at the University of Pennsylvania (Penn Medicine).
  • Its design allows for safe implantation and removal by neurosurgeons without causing harm to delicate brain tissue.
  • Dr. Ben Rapoport, Chief Science Officer and co-founder of Precision Neuroscience, underscored the significance of these studies in advancing both medical science and patient care.
  • This partnership aims to explore the diverse applications of high-resolution cortical surface arrays in clinical settings, ranging from intraoperative monitoring to neurocritical care.

ONWARD® Medical Launches Capital Increase by Way of an Accelerated Bookbuild Offering and of a Public Offering in France for an Indicative Amount of EUR 15 Million, with an Up to EUR 5 Million Upsize Option

Retrieved on: 
Wednesday, March 20, 2024
Brussels Stock Exchange, SCI, Public, Private, KBC, VWAP, ARC, Hand, Acceleration, Regulation, DSM-IV codes, CSO, Movement, EUR, Private placement, BCI, Offerings, Public offering, Equity carve-out, Euronext, Issue, Euronext Amsterdam, Security (finance)

The final number of New Shares placed and the issue price per New Share (the “Issue Price”) will be announced after pricing of the Offerings.

Key Points: 
  • The final number of New Shares placed and the issue price per New Share (the “Issue Price”) will be announced after pricing of the Offerings.
  • The New Shares will be issued from the Company’s authorized capital under exclusion of the existing shareholders’ pre-emptive rights.
  • “It is the Company’s intention to raise gross proceeds of indicatively EUR 15 million from the Offerings, with an up to EUR 5 million upsize option.
  • A separate announcement will be made shortly regarding the Public Offer in France via the PrimaryBid platform and its terms.

ONWARD® Medical Launches Capital Increase by Way of an Accelerated Bookbuild Offering and of a Public Offering in France for an Indicative Amount of EUR 15 Million, with an Up to EUR 5 Million Upsize Option

Retrieved on: 
Wednesday, March 20, 2024
Failure, Economy, Brussels Stock Exchange, Exercise, Patient, Risk, European, Intellectual property, Marketing, SCI, Annual, Public, Private, KBC, AFM, Prospectus, Royal Victorian Order, VWAP, ARC, Hand, Acceleration, Part, Research, Classification, Enrollment, Certification, DSM-IV codes, CSO, FDA, Movement, Engineering, EUR, Private placement, BCI, Offerings, Public offering, Market, Issue, Euronext Amsterdam, Probability, Security (finance)

The Issue Price will be determined by the accelerated book-building initiated with institutional investors.

Key Points: 
  • The Issue Price will be determined by the accelerated book-building initiated with institutional investors.
  • The Public Offering will not extent to retail investors located outside of France.
  • The New Shares will be issued from the Company’s authorized capital under exclusion of the existing shareholders’ pre-emptive rights.
  • It is the Company’s intention to raise gross proceeds of approximately €15.0 million from the Offerings, with an up to €5 million upsize option.

ONWARD® Medical Successfully Completes Benchmark Testing on Path to Commercialize ARC-EX® System

Retrieved on: 
Monday, March 18, 2024
BCI, Paralysis, Euronext, ARC, Movement, SCI, Medical device

  EINDHOVEN, the Netherlands, March 18, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announces receipt of a positive report from a leading US-based medical equipment testing laboratory confirming its investigational ARC-EX System conforms to prevailing electrical standards, a requirement for commercial launch.  

Key Points: 
  • Last year, the Company announced its decision to update the ARC-EX printed circuit board assembly.
  • With the positive testing report, the Company moves closer to meeting regulatory obligations for market launch.
  • The ONWARD ARC-EX System is designed to improve upper extremity movement after paralysis caused by spinal cord injury.
  • “The positive tests are an important milestone on our path to commercialize the external, non-invasive ARC-EX System in the US later this year,” said ONWARD Medical CEO Dave Marver.